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Abstract
Aim: To evaluate the effects of preventive treatment with low-level laser therapy (LLLT) on progression of dystrophy in mdx
mice.
Methods: Ten animals were randomly divided into 2 experimental groups treated with superpulsed LLLT (904 nm, 15 mW,
700 Hz, 1 J) or placebo-LLLT at one point overlying the tibialis anterior muscle (bilaterally) 5 times per week for 14 weeks
(from 6th to 20th week of age). Morphological changes, creatine kinase (CK) activity and mRNA gene expression were
assessed in animals at 20th week of age.
Results: Animals treated with LLLT showed very few morphological changes in skeletal muscle, with less atrophy and
fibrosis than animals treated with placebo-LLLT. CK was significantly lower (p = 0.0203) in animals treated with LLLT
(864.70 U.l21, SEM 226.10) than placebo (1708.00 U.l21, SEM 184.60). mRNA gene expression of inflammatory markers was
significantly decreased by treatment with LLLT (p,0.05): TNF-a (placebo-control = 0.51 mg/ml [SEM 0.12], - LLLT = 0.048 mg/ml
[SEM 0.01]), IL-1b (placebo-control = 2.292 mg/ml [SEM 0.74], - LLLT = 0.12 mg/ml [SEM 0.03]), IL-6 (placebo-control = 3.946 mg/
ml [SEM 0.98], - LLLT = 0.854 mg/ml [SEM 0.33]), IL-10 (placebo-control = 1.116 mg/ml [SEM 0.22], - LLLT = 0.352 mg/ml [SEM
0.15]), and COX-2 (placebo-control = 4.984 mg/ml [SEM 1.18], LLLT = 1.470 mg/ml [SEM 0.73]).
Conclusion: Irradiation of superpulsed LLLT on successive days five times per week for 14 weeks decreased morphological
changes, skeletal muscle damage and inflammation in mdx mice. This indicates that LLLT has potential to decrease
progression of Duchenne muscular dystrophy.
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Introduction
Duchenne muscular dystrophy (DMD) is a recessive X-linked
variety of muscular dystrophy affecting one in every 3500 males
[1–3]. DMD is caused by mutation of the dystrophin gene at Xp21
resulting in an absence of the protein dystrophin. Symptoms
usually arise between 3 to 5 years of age, and include calf muscle
pseudohypertrophy, weakness of the proximal muscles (especially
lower limbs) and abnormal gait. As the disease progresses through
teenage years respiratory complications may appear in addition to
headaches, nausea and fatigue [2–4]. Most individuals with DMD
die by 30 years of age due these complications [3,5]. There is no
cure for the disease so the goal of treatment is to control symptoms
to improve quality of life.
The most widely used preclinical model to study the degener-
ation and regeneration of muscle in DMD is the mdx (C57BL/
10ScSn-Dmdmdx/J) mouse model. Mdx mice have a point mutation
within the dystrophin gene preventing the expression and synthesis
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of dystrophin resulting in dystrophic-like symptoms similar to that
seen in humans [3,6,7]. In early life (3 weeks) mdx mice present
with periods of skeletal muscle degeneration and regeneration and
as the animal ages (8 weeks) muscle atrophy and fibrosis develop
[8]. Muscle fiber degeneration is accompanied by inflammatory
and immune responses with death occurring prematurely in most
mice at 24 months [9].
Inflammatory and immune responses have a critical role in the
pathogenesis of DMD [9] so anti-inflammatory glucocorticoids
(corticosteroids) are used as mainstay pharmacological treatment
although they often lead to severe side-effects in the long-term and
are often abandoned.
The term LASER means Light Amplification by Stimulated
Emission of Radiation. Laser was developed at 1960s, and is light
with special proprieties including monochromaticity and low
divergence. Low-level laser therapy (LLLT) is the application of
light for therapeutic purposes usually using a class 3B laser device
with a mean output range of 10 mW–500 mW. There is strong
evidence that LLLT promotes tissue regeneration, reduces
inflammation and relieves pain [10–12]. The light used in LLLT
is typically of narrow spectral width and in the red or near infrared
(NIR) spectrum (600 nm–1000 nm), with a power density
(irradiance) between 1 mW to 5 W/cm2 [13].
The first placebo-controlled clinical LLLT trial in musculoskel-
etal pain was published in 1980 and found that LLLT improved
erythema, pain and grip strength in patients with rheumatoid
arthritis of the hands [14]. Since then there has been a steady
growth of evidence of efficacy for the management of various
conditions including osteoarthritis [15] tendinopathies [10,16],
wounds [17,18], back pain [19], neck pain [12,20], peripheral
nerve injuries [21] and stroke [22]. A major advantage of LLLT
over pharmacological management is that there are minimal side-
effects.
The use of LLLT to manage skeletal muscle fatigue and
facilitate skeletal muscle recovery is a novel area of research.
Recent studies performed by our research group have shown that
when LLLT and light emitting diode therapy (LEDT) are applied
before exercise the onset of skeletal muscle fatigue is delayed in
both animals and humans and the status of biochemical markers
related to skeletal muscle recovery is improved [23–32]. These
findings suggest that LLLT may have protective effects on skeletal
muscle tissue.
Evidence suggests that LLLT has physiological effects that may
influence soft tissue metabolism in various pathologies including
increased microcirculation [33], enhanced ATP synthesis and
stimulating of mitochondrial respiratory chain [34] and mito-
chondrial function [35]. There are also reports that LLLT reduces
the release of reactive oxygen species (ROS) and the activity of
creatine kinase (CK, also known as creatine phosphokinase), and
increases the production of antioxidants and heat shock proteins
[36,37].
With this perspective in mind, the aim of this study was to
evaluate effects of preventive treatment with LLLT on progression
of dystrophy in mdx mice, assessing skeletal muscle morphology,
skeletal muscle damage and inflammation.
Table 1. Superpulsed LLLT parameters.
Placebo-control group LLLT group
Wavelength: 904 nm 904 nm
Peak power: 0 W 10.4 W
Pulse width: - 180 ns
Pulse frequency: - 700 Hz
Average power: 0 mW 15 mW
Illuminated area per hind limb: 0.2 cm2 0.2 cm2
Peak irradiance: 0 W/cm2 52 W/cm2
Average irradiance: 0 mW/cm2 75 mW/cm2
Time: 67 s per hind limb 67 s per hind limb
Energy: 0 J 1.005 J
Fluence: 0 J/cm2 5.025 J/cm2
doi:10.1371/journal.pone.0089453.t001
Figure 1. LLLT irradiation being performed to mdx mice.
doi:10.1371/journal.pone.0089453.g001
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Materials and Methods
Animals
The experiments were started with 6 weeks old male mdx mice,
housed in central animal house of Nove de Julho University with a
12-hours light/dark cycle and food and water ad libitum. Animals
were purchased from the central animal house of Federal
University of Sa˜o Paulo (UNIFESP), Brazil. The study was
conducted in accordance with policies and procedures of Brazilian
laws and the Department of Health and Human Services in the
USA. The experimental protocol was submitted and approved by
the Animal Research and Care Committee of the Nove de Julho
University, Sao Paulo, Brazil.
Experimental groups
Ten animals were randomly divided into 2 experimental groups
with 5 animals in each group:
N Placebo-control group: animals were treated with placebo
LLLT (using a placebo laser probe) over the tibialis anterior
muscle (bilaterally) for 5 times per week (Monday to Friday) for
14 weeks.
N LLLT group: animals were treated with active LLLT over the
tibialis anterior muscle (bilaterally) for 5 times per week
(Monday to Friday) for 14 weeks.
Animals were sacrificed at 20 weeks of age with an overdose of
halothane 24 hours after the last LLLT treatment. After the
removal of skin and connective tissue, tibialis anterior muscles
were removed and processed for further analysis. Blood samples
for creatine kinase (CK) analysis were collected by a single heart
puncture.
Procedures
Superpulsed LLLT treatment. A GaAs diode superpulsed
laser with a frequency of 700 Hz, mean output power of 15 mW
Figure 2. Photomicrograph of morphological aspects in muscle tissue of control group. Figure 1a (placebo-control group - transversal):
large amount of fibrous tissue (A), nuclei dislocated to the center of muscle fibers (B), decreased number of muscle fibers (C), and decreased size of
muscle fibers (D), Magnification:6100. Figure 1b (placebo-control group - transversal): large amount of fibrous tissue (A), nuclei dislocated to center
of muscle fiber (B), decreased number of muscle fibers (C), and decreased size of muscle fibers (D), Magnification:6400. Figure 1c (placebo-control
group - longitudinal): large amount of fibrous tissue (A), nuclei dislocated to center of muscle fiber (B), clustering of nuclei in the center of muscle
fiber (C), and decreased number of muscle fibers (D), Magnification:6100. Figure 1d (placebo-control group - longitudinal): large amount of fibrous
tissue (A), nuclei dislocated to center of muscle fiber (B), clustering of nuclei in the center of the muscle fibers (C), and decreased size of muscle fibers
(D), Magnification:6400.
doi:10.1371/journal.pone.0089453.g002
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and wavelength of 904 nm (infrared) was used. A complete
description of LLLT parameters is presented in table 1.
The optical power of the laser device was calibrated with a
Newport multifunction optical meter model 1835C, before, during
and after the experiment. The stability of the laser output during
laser irradiation was measured by collecting light with a partial
reflect (4%). The spot size was 0.2 cm2, and the laser illumination
spot was placed in direct contact with the skin (shaved) overlying
the central part of tibialis anterior muscle. Animals received
irradiation at this single point (bilaterally) 5 times per week
(Monday to Friday) for 14 weeks. Irradiation lasted 67 s, with a
fixed power density of 75 mW/cm2. The total delivered energy
was 1.0 J per session for the LLLT group. The placebo-control
group was treated in an identical manner using an identical laser
probe that delivered 0 mW of output power (i.e. a placebo laser
probe). The therapist who performed the treatment was blinded to
group allocation. The energy dose chosen was based on two
previous studies performed by our research group using identical
LLLT parameters that found that LLLT protected skeletal muscle
tissue by delaying skeletal muscle fatigue and improving
biochemical markers of skeletal muscle damage in rats [28,30].
Figure 1 illustrates the laser irradiation being performed.
Outcomes
Analyses of histology, blood and PCR of biochemical markers
were performed by a blinded observer.
Histology. Muscle tissue samples were fixed in a 10%
formalin solution for 72 hours and then dehydrated in a series
of alcohol baths beginning with 50% and progressing to 100%
(SYNTH) and cleared in xylol for 4 hours (SYNTH). The samples
were placed in adequate aluminum recipients with Paraplast for
4 hours for impregnation and then placed in a small recipient,
covered with paraffin and left to harden, forming a block
containing the tissue sample. Slices measuring 5 mm in thickness
were cut on a microtome (LEICA RM 2125 RT), washed and
placed in a water bath. The cuts were stained with hematoxylin
and eosin and mounted on permanent slides for subsequent
analysis under an optical microscope (Nikon, Eclipse E-200 model,
Figure 3. Photomicrograph of morphological aspects in muscle tissue of LLLT groups. Figure 2a (LLLT group - transversal): small amount
of fibrous tissue (A), nuclei situated in the periphery of muscle fibers (B), majority of muscle fibers normal (C), and majority of muscle fibers of normal
size (D), Magnification:6100. Figure 2b (LLLT group - transversal): small amount of fibrous tissue (A), nuclei situated in the periphery of muscle fibers
(B), normal number of muscle fibers (C), and majority of muscle fibers of normal size (D), Magnification:6400. Figure 2c (LLLT group - longitudinal):
small amount of fibrous tissue (A), nuclei situated in the periphery of muscle fibers (B), small clustering of nuclei in the center of muscle fiber (C), and
normal number of muscle fibers (D), Magnification:6100 Figure 2d (LLLT group - longitudinal): small amount of fibrous tissue (A), nuclei situated in
the periphery of muscle fibers (B), normal number of muscle fibers (C), and increased size of muscle fibers (D), Magnification:6400.
doi:10.1371/journal.pone.0089453.g003
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China). The specimens were photographed using a microphoto-
graphic camera (Dino-Lite Digital Microscope, DinoEye
AM423X model, Brazil) connected to a microcomputer. Stan-
dardized photos were taken of all groups at magnifications of
6100 and6400.
CK analysis. For the analysis of CK, 3 ml of blood were
collected from each animal through heart puncture immediately
prior to euthanasia. The material was centrifuged and the
supernatant analyzed. CK was determined using the Labtest
commercial kit (Brazil). One ml of the working reagent was pipetted;
0.02 ml of the serum sample was homogenized and immediately
transferred to a cubette at 37uC for 2 minutes. The reading of the
initial absorbance was performed using an enzyme-linked immuno-
sorbent assay following the instructions of the commercial kit.
RNA isolation and real-time polymerase chain reaction
(RT-PCR) analysis. Firstly, muscles were thawed, and Trizol
was immediately added (Gibco BRL, Life Technologies, Rockville,
MD, USA, 1 ml/100 mg tissue). Then, muscles were homoge-
nized for the recovery of total RNA, according to the manufac-
turer’s instruction.
DNase I was employed to digest DNA to obtain RNA
purification and the integrity of RNA was verified by agarose gel
electrophoresis. Total RNA (2 mg) was used for first-strand cDNA
synthesis [reverse transcriptase (RT)] using SuperScript II. In
addition, RNaseOUT was also added to protect the RNA during
this process. Three pooled RNA aliquots were routinely sham
reverse transcribed (i.e. reverse transcriptase omitted) to ensure the
absence of DNA contaminants. Diluted RT samples (1:10) were
submitted to Real Time PCR amplification using Platinum Sybr
QPCR Supermix-UDG and specific oligonucleotides (designed
using http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The
primers used were: TNF-a (forward: CCACCACGCTCTTCTG-
TCTA; reverse: AGGGTCTGGGCCATAGAACT), IL-1b (for-
ward: TTGACGGACCCCAAAAGATG; reverse: AGAAGGT-
GCTCATGTCCTCAT), IL-6 (forward: GAGCCCACCAAGA-
ACGATAG; reverse: TCAGTCCCAAGAAGGCAACT), IL-10
(forward: CAGCCGGGAAGACAATAACT; reverse: ATGTTG-
TCCAGCTGGTCCTT), COX-2 (forward: TGAGCACAG-
GATTTGACCAG; reverse: CCTTGAAGTGGGTCAGGATG),
HPRT was used as an internal control (forward: TCCTCCTC-
AGACCGCTTT; reverse: TTTTCCAAATCCTCGGCATAA-
TG).
The conditions for PCR were as follows: 50uC – 2 min; 95uC –
2 min, followed by 30 cycles of 95uC – 15 sec; 60uC – 1 min,
followed by 72uC – 15 sec. Cycle threshold (Ct) values were
recorded for each gene, and the results of genes of interest were
normalized to results obtained with the internal control gene.
Delta-Delta-Ct (ddCt) values were calculated and results expressed
as fold increases. All oligonucleotides and reagents utilized were
purchased from Invitrogen Co. (USA).
Statistical Analysis
All data were normally distributed so statistical analysis was
performed using two-tailed unpaired t-tests. The statistical level of
significance was set at p,0.05.
Results
The analysis of animals in the placebo-control group showed
extensive fibrosis, decreased number of muscle fibers, decreased
size of muscle fibers and clustering of nuclei in the center of muscle
fibers indicative of a degenerative process of muscle tissue.
Animals in the LLLT group had limited fibrosis, normal number
and size of muscle fibers and nuclei in the periphery of muscle
fibers indicative of delayed progression of pathological changes in
the skeletal muscle tissue. Morphological aspects of skeletal muscle
tissue in placebo-control group and LLLT group are shown in
figures 2 and 3.
CK activity, indicative of muscle damage, was significantly
lower (p = 0.0203) in the LLLT group (864.70 U.l21, SEM
226.10) compared with the placebo-control group
(1708.00 U.l21, SEM 184.60, figure 4).
mRNA gene expression of inflammatory markers was
significantly lower in the LLLT group compared with the
placebo-control group. TNF-a gene expression levels were
0.51 mg/ml (SEM 0.12) in placebo-control group and 0.048 mg/
ml (SEM 0.01) in LLLT group (p = 0.0042). IL-1b was 2.292 mg/ml
(SEM 0.74) in the placebo-control group and 0.12 mg/ml (SEM
0.03) in the LLLT group (p = 0.0189). mRNA gene expression of
IL-6 was 3.946 mg/ml (SEM 0.98) in the placebo-control group
and 0.854 mg/ml (SEM 0.33) in the LLLT group (SEM
p=0.0174). IL-10 was 1.116 mg/ml (SEM 0.22) in the placebo-
control group and 0.352 mg/ml (SEM 0.15) in the LLLT group
(p = 0.0218). mRNA gene expression of COX-2 was 4.984 mg/ml
(SEM 1.18) in the placebo-control group and 1.470 mg/ml (SEM
0.73) in the LLLT group (p = 0.0355). The results of mRNA gene
expression of inflammatory markers are summarized in figures 5.
Discussion
This study used gene-deficient mdx mice as an experimental
model of DMD [38]. Fibrosis and inflammation have critical roles
in the progression of DMD [9] and therefore treatment with
glucocorticoid drugs which have anti-inflammatory actions is
widely used [39]. Non-steroidal anti-inflammatory drugs (NSAIDs)
are also a treatment option [40]. Longitudinal studies find that
glucorticoids are beneficial in the management of DMD by
prolonging self-ambulation, reducing the need for scoliosis surgery
[41] and delaying the onset of cardiomyopathy [42]. However,
high quality evidence from randomized controlled trials is lacking
and glucocorticoids have side-effects on bone growth resulting in
treatment having to be abandoned [39,43]. Consequently
alternative approaches to reduce inflammation, fibrosis and
necrosis are being considered. Therapeutic targets include nuclear
Figure 4. CK activity levels in the placebo-control group and in
the LLLT group (n =5 animals per group). The * indicates
significant difference compared with placebo-control group
(p = 0.0203). Error bars indicate SEM.
doi:10.1371/journal.pone.0089453.g004
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hormone receptors, calcium channels and NADPH-oxidases.
Promising targets to counteract DMD progression also include
strategies to inhibit nuclear factor-kappaB (NF-kappaB),
transforming growth factor-alpha (TGF-alpha), transforming
growth factor-beta (TGF-beta) and inhibiting the production or
action myostatin [39].
Figure 5. mRNA gene expression of TNF-a, IL-1b, IL-6, IL-10, and COX-2 in placebo-control group and LLLT group (n=5 animals per
group). The * indicates a significant difference compared with placebo-control group (p = 0.0042 for TNF-a, p = 0.0189 for IL-1b, p = 0.0174 for IL-6,
p = 0.0218 for IL-10, and p=0.0355 for COX-2, respectively). Error bars indicate SEM.
doi:10.1371/journal.pone.0089453.g005
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To our knowledge this is the first study to investigate the effect
of LLLT on the progression of DMD. Over the years LLLT has
been used to treat a variety of inflammatory disorders like
osteoarthritis [15], tendinopathies [10,16] and acute cancer
therapy-induced oral mucositis [44]. Several studies on animals
and humans have shown that LLLT with both red and infrared
wavelengths modulates the release of inflammatory markers
including PGE2, TNF-a, IL-1b and plasminogen activator [45].
LLLT also modulates several aspects of the inflammatory process
including oedema and hemorrhagic formation, necrosis, neutro-
phil cell influx and the activity of macrophages, lymphocytes and
neutrophils [10,46–49]. LLLT has been shown to inhibit the NF–
Kappa signaling pathway [50] and to modulate expression of
inducible nitric oxide synthase (iNOS) [51].
Our placebo-controlled study found that LLLT decreased
mRNA gene expression of various inflammatory markers includ-
ing TNF-a, IL-1b, IL-6, IL-10 and COX-2. This suggests that
LLLT has protective effects on skeletal muscle tissue. Further-
more, CK activity was significantly lower in the LLLT group
compared with the placebo-control group and this suggests that
LLLT reduced the progression of muscle damage. Reduction of
CK activity has also been reported after successful glucocorticoid
therapy and is associated with clinical benefit [52].
Previous studies performed by our research group using rats
have found that LLLT delivered using a 904 nm wavelength and a
dose of 1 J irradiated before tetanic contractions significantly
increased skeletal muscle performance [28,30], and significantly
decreased CK activity [28,30] and COX-2 mRNA gene
expression [30]. Recently, Hayworth et al. [53] found that a
single dose of LLLT increased cytochrome c-oxidase activity in
intact skeletal muscle tissue 24 hours after irradiation. Addition-
ally, there was a dose and fiber type-dependent increase in
cytochrome c-oxidase in skeletal muscle fibers suggesting that
LLLT up-regulated mitochondrial activity increasing ATP pro-
duction into muscle cells and decreasing oxidative stress and ROS
production. These effects may contribute to the mechanism by
which LLLT protects skeletal muscle against degeneration.
We recognize that our study evaluated morphological aspects of
skeletal muscle, biochemical marker of damage and gene
expression of inflammatory markers in an animal model, so we
understand that this represents a limitation and we express caution
at extrapolating our findings into humans at this stage. Neverthe-
less, LLLT has a strong safety profile and reports of side effects in
an evidence base of over 200 randomized controlled clinical trials
are few and minor. Therefore, we believe serious consideration
should be given to the potential of LLLT as a treatment option of
long-term conditions like DMD. Future studies would include
investigation of the effects of LLLT on protein expression of
inflammatory markers and functional aspects of DMD and the
determination of optimal parameters to inform the design of
robust clinical trials. We hope that our findings may initiate
interest in the use of LLLT as a potentially useful adjunct for
DMD.
Conclusion
Superpulsed LLLT administered using a wavelength of 904 nm
and dose of 1 J on successive days, 5 times per week for 14 weeks
decreased morphological changes, skeletal muscle damage and
inflammation in mdx mice. This suggests that LLLT may decrease
progression of DMD. Further studies are needed to elucidate the
mechanism of action, effects on functional outcomes and to
establish optimal parameters of application to inform clinical use.
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